

## PAPER

[View Article Online](#)  
[View Journal](#) | [View Issue](#)Cite this: *Dalton Trans.*, 2023, **52**, 11349Platinum(IV) combo prodrugs containing cyclohexane-1*R*,2*R*-diamine, valproic acid, and perillic acid as a multiaction chemotherapeutic platform for colon cancer†Elisabetta Gabano,<sup>‡a</sup> Marzia Bruna Gariboldi,<sup>‡b</sup> Emanuela Marras,<sup>b</sup> Francesca Barbato<sup>c</sup> and Mauro Ravera<sup>‡\*c</sup>

The complex [PtCl<sub>2</sub>(cyclohexane-1*R*,2*R*-diamine)] has been combined in a Pt(IV) molecule with two different bioactive molecules (*i.e.*, the histone deacetylase inhibitor 2-propylpentanoic acid or valproic acid, **VPA**, and the potential antimetastatic molecule 4-isopropenylcyclohexene-1-carboxylic acid or perillic acid, **PA**) in order to obtain a set of multiaction or multitarget antiproliferative agents. In addition to traditional thermal synthetic procedures, microwave-assisted heating was used to speed up their preparation. All Pt(IV) complexes showed antiproliferative activity on four human colon cancer cell lines (namely HCT116, HCT8, RKO and HT29) in the nanomolar range, considerably better than those of [PtCl<sub>2</sub>(cyclohexane-1*R*,2*R*-diamine)], **VPA**, **PA**, and the reference drug oxaliplatin. The synthesized complexes showed pro-apoptotic and pro-necrotic effects and the ability to induce cell cycle alterations. Moreover, the downregulation of histone deacetylase activity, leading to an increase in histone H3 and H4 levels, and the antimigratory activity, indicated by the reduction of the levels of matrix metalloproteinases MMP2 and MMP9, demonstrated the multiaction nature of the complexes, which showed biological properties similar to or better than those of **VPA** and **PA**, but at lower concentrations, probably due to the lipophilicity of the combo molecule that increases the intracellular concentration of the single components (*i.e.*, [PtCl<sub>2</sub>(cyclohexane-1*R*,2*R*-diamine)], **VPA** and **PA**).

Received 16th June 2023,  
Accepted 18th July 2023

DOI: 10.1039/d3dt01876h

rsc.li/dalton

## Introduction

Although over the years Pt(IV) complexes have not succeeded to be a serious alternative to traditional Pt(II) anticancer agents, they are still widely studied because of their characteristics that make them particularly suitable for the design of metal-based drugs with tailored properties. Actually, octahedral Pt(IV) complexes can reach intact cancer cells and the hypoxic tumor environment can activate them by reductive elimination of their axial ligands, thus releasing the corresponding cytotoxic Pt(II) metabolites (*activation by reduction*) and increasing the

selectivity of the drugs.<sup>1–6</sup> In addition, the axial ligands provide that something extra that makes Pt(IV) complexes so interesting. As a matter of fact, the axial ligands that will be released after reduction can be designed to play a role in the overall activity of the Pt(IV) complexes. They can be tumor-targeting molecules (hormones, folates, amino acids, peptides, carbohydrates, *etc.*), pharmaceutical agents (*e.g.*, enzyme inhibitors), or anticancer drugs with a different mechanism of action, able to synergize with the Pt(II) metabolites. Such multi-action or multitarget prodrugs must contain one or more complementary bioactive molecules.<sup>7–13</sup> Apart from the specific role of the ligands, the multi-action Pt(IV) complexes are generally more active than their free components administered separately, as the combination gains in lipophilicity and, thus, in cellular uptake, ensuring high intracellular levels of both the cytotoxic Pt(II) metabolites and the organic active biomolecules (synergistic cellular accumulation).<sup>12,14,15</sup>


In this work, (SP-4-2)-(cyclohexane-1*R*,2*R*-diamine)dichloridoplatinum(II) ([PtCl<sub>2</sub>(dach)] or **1**, Scheme 1; dach = cyclohexane-1*R*,2*R*-diamine) has been combined with two different bioactive molecules (*i.e.*, 2-propylpentanoic acid or valproic acid, **VPA**, and 4-isopropenylcyclohexene-1-carboxylic acid or

<sup>a</sup>Dipartimento per lo Sviluppo Sostenibile e la Transizione Ecologica, Università del Piemonte Orientale, Piazza Sant'Eusebio 5, 13100 Vercelli, Italy<sup>b</sup>Dipartimento di Biotecnologie e Scienze della Vita (DBSV), Università dell'Insubria, via Dunant 3, Varese, Italy<sup>c</sup>Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, Viale Michel 11, 15121 Alessandria, Italy.

E-mail: mauro.ravera@uniupo.it

†Electronic supplementary information (ESI) available: <sup>1</sup>H, <sup>13</sup>C, <sup>195</sup>Pt, and [<sup>1</sup>H, <sup>13</sup>C] HSQC NMR spectra of complexes 4–9. See DOI: <https://doi.org/10.1039/d3dt01876h>

‡These authors contributed equally.



**Scheme 1** Sketch of the complexes under investigation and the corresponding synthetic pathways: (i)  $\text{H}_2\text{O}_2/\text{CH}_3\text{COOH}$ ; (ii)  $\text{H}_2\text{O}_2/\text{H}_2\text{O}$ ; (iii) acyl chloride of **PA**, microwave heating,  $\text{CH}_3\text{CN}$ , pyridine; (iv) acyl chloride of **VPA**, microwave heating,  $\text{CH}_3\text{CN}$ , pyridine; (v) perillic anhydride, DMSO. The numbering scheme for the assignment of NMR signals is reported in the ESI; **PA** = perillic acid, **VPA** = valproic acid.

perillic acid, **PA**) in a set of different  $\text{Pt(IV)}$  complexes in order to obtain the final multifunctional ‘combo’ molecules (Scheme 1) showing properties better than those of the single components.

The dach ligand imparts peculiar characteristics to  $\text{Pt(II)}$  complexes, being present in the anticancer drug oxaliplatin, (*SP-4-2*)(cyclohexane-1*R*,2*R*-diamine)(ethanedioato)platinum (ii). Computer modeling showed that the cyclohexane ring protrudes directly outward into the major groove of the bound DNA, markedly altering the area of the adduct.<sup>16,17</sup> The differences in the structure of the adduct produced by cisplatin and oxaliplatin are consistent with the observation that they are differentially recognized by the DNA mismatch repair system, with cisplatin being more easily recognized, making  $\text{Pt(II)}$ -dach complexes an interesting escape route to bypass cisplatin-resistance.<sup>18,19</sup> In particular, **1** was chosen as the equatorial structure based on previous experience acquired by the authors on both the synthesis and the study of the biological properties of this synthon and its  $\text{Pt(IV)}$  derivatives. Moreover, such  $\text{Pt(IV)}$  prodrugs show relatively high cellular uptake and good antiproliferative activity, and the presence of dach itself could increase cancer cell aggression by the immune system through immunogenic cell death (ICD).<sup>20</sup> In contrast, other authors prefer the use of oxaliplatin, because its  $\text{Pt(IV)}$  derivatives can be more stable *in vitro* and more persistent *in vivo*, even though this depends on the nature of the coordinated ligands.<sup>5,21–23</sup>

**VPA** is a well-known histone deacetylase (HDAC) inhibitor. The abnormal enhancement of some members of the HDAC family has been closely related to the appearance and development of various malignant tumors. In addition, changes in the expression and mutation of HDAC-encoding genes have been associated with tumor growth, due to their ability to induce abnormal transcription of genes that regulate key cell functions, such as cell proliferation, cell-cycle regulation, and apoptosis. For this reason, HDAC inhibitors (HDACIs) can induce growth arrest, differentiation, or apoptosis, to a variable extent, *in vitro* and *in vivo*. Noticeably, normal cells are usually more resistant than tumor cells to HDACIs.<sup>24–27</sup> The combination of HDACIs as chemosensitizers with other cancer therapeutics has shown great potential in preclinical and therefore clinical trials and may represent a way to achieve complete therapeutic benefits.<sup>28–32</sup> Different HDAC inhibitors have already been linked in the axial positions of  $\text{Pt(IV)}$  cores, showing synergistic activity with  $\text{Pt(II)}$  metabolites.<sup>14,15,20,33–40</sup>

**PA**, an active metabolite of limonene, is capable of inhibiting farnesyltransferase (FTase) and geranylgeranyltransferase (GGTase I), the enzymes that catalyze protein prenylation.<sup>41</sup> This is necessary for the cellular activity of many oncogenic proteins, including some members of the Ras family. Therefore, prenylation inhibitors are promising for antitumor therapy blocking Ras signaling.<sup>42–46</sup> Moreover, **PA** exhibits good *in vivo* antimetastatic activity,<sup>47</sup> modulates the immune system,<sup>48</sup> and acts as a radiosensitizer.<sup>49</sup> Recently, a cisplatin-



based Pt(IV) complex with two molecules of **PA** was shown to exhibit high antiproliferative and antimetastatic activity at nanomolar concentrations in lung A-549 cancer cells.<sup>50</sup>

On the basis of the described activities of **VPA** and **PA**, we herein report the design, synthesis, characterization, and biological activities of Pt(IV) derivatives containing different combinations of the two organic ligands. Oxaliplatin in combination with fluorouracil and leucovorin has shown a definite role in the treatment of colorectal cancer (FOLFOX4 regimen). For this reason, the activity of the Pt(IV) derivatives was evaluated in HCT116, HCT8, RKO, and HT29 colon cancer cells, and their effects on HDAC and cell migration were studied to elucidate the mechanism of action of the compounds and reveal the possible multiple effects of some of them.

## Results and discussion

### Synthesis and characterization

The Pt(IV) complexes under investigation were synthesized by oxidizing [PtCl<sub>2</sub>(dach)], **1**,<sup>51,52</sup> with hydrogen peroxide in acetic acid (complex **2**) or in water (complex **3**) (Scheme 1).<sup>53,54</sup> For the subsequent substitution reaction, **PA** and **VPA** had to be turned into a more reactive form, that is, acyl chloride or anhydride, using oxalyl chloride in the presence of a catalytic amount of dimethylformamide or the coupling agent *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride, respectively. Reactions of **2** and **3** with acyl chlorides were carried out in acetonitrile with microwave-assisted heating to obtain complexes **4–7**.<sup>55</sup> The reaction of **3** with perillaldehyde anhydride required the use of DMSO as a solvent to favor the formation of monosubstituted complex **8**.<sup>56</sup> Finally, this intermediate was turned into trifunctional complex **9** upon reaction with **VPA** acyl chloride as described above.

All complexes were characterized by RP-HPLC/ESI-MS and NMR spectroscopy using mono- and bidimensional techniques (see ESI, Fig. S1–S27,† for the most relevant NMR spectra). The dach ligand is supposed to be in a chair configuration, as observed in other similar structures,<sup>57,58</sup> but, when the axial ligands are different, couples of corresponding carbon atoms are no longer equivalent and resonate at different frequencies in <sup>13</sup>C NMR spectra. As far as the NH<sub>2</sub> groups of coordinated

dach are concerned, in the <sup>1</sup>H spectra in DMSO-d<sub>6</sub> of complexes with different axial ligands, four different signals are visible; whereas, when the axial ligands are equal, only two signals are observed. The chemical shift of such signals varies with the change of the other ligands. These features of dach ligands in Pt(IV) complexes have been observed for similar complexes.<sup>54</sup> Also, the signals of **VPA** chains are affected by the other ligands, which results in not-perfectly-equivalent nuclei and the corresponding splitting of most signals. The <sup>195</sup>Pt NMR signals of the final dicarboxylato complexes exhibit chemical shifts within the range of 1070–1115 ppm that are consistent with the expected coordination sphere of such Pt(IV) complexes.<sup>59–67</sup>

The final compounds **4–7** and **9** are supposed to be quite lipophilic and a RP-HPLC technique was used to measure their relative lipophilicity, associated with the ability to cross cell membranes passively.<sup>68</sup> This is possible since retention is due to partitioning between the hydrophobic stationary phase (model of cell membranes) and the aqueous mobile phase (model of the environment inside and outside cells).<sup>66,69</sup> The retention time (*t<sub>R</sub>*) of the complexes was measured on a C18 column employing a 30/70 mixture of 15 mM formic acid/MeOH as an eluent. Data are expressed as log *k'* (*k'* = (*t<sub>R</sub>* – *t<sub>0</sub>*)/*t<sub>0</sub>*, where *t<sub>0</sub>* is the column dead-time) and are reported in Table 1.

### Cytotoxicity

The effect of Pt(IV) derivatives on four different human colon cancer cell lines, namely HCT116, RKO, HCT8, and HT29, was evaluated. Cell viability was assessed by the MTT assay upon treatment with increasing concentration of the compounds studied. Compounds **1**, oxaliplatin, **VPA**, and **PA** were added to the experiments as references. The antiproliferative effect of the compounds was quantitated by calculating the drug concentration that inhibits tumor cell viability by 50% (half-maximal inhibitory concentration, IC<sub>50</sub>) from the respective dose–response curves (Table 1). Unlike **VPA** and **PA**, for which the IC<sub>50</sub> values were found to be in the order of hundreds of micromoles per liter, all new Pt(IV) derivatives showed cytotoxic effects at nanomolar concentrations. Taking into account only the new Pt(IV) derivatives, **4**, **5**, **6**, **7** and **9** showed higher potency than their precursor, namely **1**. Interestingly, **6** and **9**

**Table 1** Lipophilicity data (log *k'*) and IC<sub>50</sub> values (nM) obtained in HCT116, HCT8, RKO, and HT29 cells by the MTT assay after 72 h of treatment with the studied derivatives and the MTT assay (mean ± S.E. of five independent experiments; #*p* < 0.001 vs. all others; \*\*\**p* < 0.001 vs. oxaliplatin, **4**, **5** and **7**)

Compound	log <i>k'</i> (70% MeOH)	IC <sub>50</sub> (nM) HCT116	IC <sub>50</sub> (nM) HCT8	IC <sub>50</sub> (nM) RKO	IC <sub>50</sub> (nM) HT29
oxaliplatin	−0.48	42.82 ± 3.07	191.62 ± 16.28	217.95 ± 46.00	261.18 ± 31.54
<b>1</b>	−0.46 <sup>40</sup>	343.19 ± 7.38 <sup>#</sup>	1377.05 ± 187.67 <sup>#</sup>	1242.68 ± 219.16 <sup>#</sup>	1659.49 ± 16.40 <sup>#</sup>
<b>4</b>	0.43	13.90 ± 1.38	44.41 ± 2.95	29.41 ± 4.38	29.41 ± 8.85
<b>5</b>	0.48	10.95 ± 3.33	34.95 ± 3.50	25.85 ± 7.42	101.01 ± 20.72
<b>6</b>	1.15	1.07 ± 0.30***	9.52 ± 1.74***	3.78 ± 0.66***	4.37 ± 0.32***
<b>7</b>	1.18	12.68 ± 4.77	34.36 ± 7.22	16.19 ± 4.02	19.69 ± 6.45
<b>9</b>	1.16	0.91 ± 0.19***	5.03 ± 0.94***	4.55 ± 1.42***	8.19 ± 1.75***
<b>PA</b>	0.55 <sup>74</sup>	(130.96 ± 22.64) × 10 <sup>3#</sup>	(154.87 ± 8.73) × 10 <sup>3#</sup>	(161.85 ± 17.3) × 10 <sup>3#</sup>	(120.67 ± 7.32) × 10 <sup>3#</sup>
<b>VPA</b>	0.56	(82.91 ± 5.25) × 10 <sup>3#</sup>	(139.68 ± 13.83) × 10 <sup>3#</sup>	(89.45 ± 9.13) × 10 <sup>3#</sup>	(112.09 ± 38.22) × 10 <sup>3#</sup>



were shown to be the most potent ones across all cell lines tested. Thus, in agreement with data reported by our group and by other authors,<sup>15,35,50</sup> these results indicate that the presence of a perillate or valproate group on the Pt(IV) molecules improved the cytotoxic effect of all progenitor molecules. Actually, as mentioned in the Introduction, a lipophilic Pt(IV) complex is able to increase the intracellular concentration of its (hydrophilic or amphiphilic) fragments by synergistic cellular accumulation when they are combined into a single molecule.

In addition, it has been widely reported that the uptake of Pt-based drugs may deeply influence their cytotoxic effects and several membrane transporters have been involved in the cytotoxicity of oxaliplatin and some Pt(IV) derivatives, including organic cation transporters (OCTs).<sup>70,71</sup> Notably, recent studies have shown increased expression of OCT1 and OCT2 in several colon cancer cells, including HCT116 and HCT8 cell lines.<sup>72,73</sup> The high potencies observed for the compounds under investigation may be explained, at least in part, also considering the potentially increased uptake of the Pt(IV) derivatives due to the increased expression of the OCT transporters.


It has been widely reported that not only Pt(II) derivatives but also **PA** and **VPA** can inhibit cancer growth through the induction of cell death, mainly apoptotic or necrotic, and cell cycle alterations.<sup>75–77</sup> Thus, to further characterize the mechanisms responsible for the cytotoxic effects of **4**, **5**, **6**, **7** and **9**, their ability to induce apoptotic and/or necrotic cell death and/or cell cycle alterations was evaluated by flow cytometric analysis. The results were then compared with those obtained by treating the cells with the reference compounds oxaliplatin, **PA**, and **VPA**, in the following experiments.

Due to its better antiproliferative activity compared to **1** (Table 1) and considering that it is one of the most widely used drugs in the treatment of colorectal cancer, oxaliplatin was used as a single reference compound for the subsequent experiments and **1** was no longer investigated.

According to previous reports,<sup>75–77</sup> **PA** and **VPA** induced apoptotic cell death in HCT116, HCT8, RKO and HT29 cell lines. Furthermore, a different degree of apoptosis was observed when cells were treated with equitoxic concentrations of Pt(IV) compounds, corresponding to the respective IC<sub>50</sub> values. As shown in Fig. 1, all Pt(IV) derivatives induced apoptotic cell death over controls in HCT116, HCT8, RKO, and HT29 cell lines. However, low percentages of apoptosis were observed in HT29 cells, compared to the other three cell lines. Interestingly, **6**, **7** and **9** induced a significantly higher extent of apoptosis compared to **PA** and **VPA** in HCT116, HCT8 and RKO cell lines.

Analysis of necrotic cell death induction in the four model cell lines under investigation showed that all compounds did not induce necrosis in the HCT116 and RKO cell lines, while a significant increase in the percentage of necrotic cells was observed in HCT8 cells treated with **5**, **6**, **7**, **9**, **PA** and **VPA**, and in HT29 cells treated with **5**, **6**, **7**, **9** and **VPA**.

The different responses, in terms of apoptotic cell death, observed in HCT116, HCT8, RKO and HT29 cells upon treat-



**Fig. 1** Percentage of apoptotic (A) and necrotic (B) HCT116, HCT8, RKO, HT29 cells after 72 h of treatment with equitoxic concentrations of the studied derivatives and reference compounds (mean  $\pm$  S.E. of three independent experiments). Statistical analysis: \* $p$  < 0.05, \*\* $p$  < 0.01 and \*\*\* $p$  < 0.001 vs. control (C).

ment with the Pt(IV) derivatives could be related to their p53 status, being mutated in the latter and wild type in the other three cell lines. As a matter of fact, it is well known that the status of the tumor suppressor gene p53 may influence the cellular response to anticancer drugs. Specifically, p53 has been related to drug resistance and resistance to apoptotic/necrotic stimuli.<sup>78,79</sup> Therefore, the results indicated that the presence of mutated p53 could account for the different apoptotic/necrotic responses to equitoxic concentrations of Pt(IV) observed in HT29 cells.

Considering that a shift in cell cycle phases, an important finding in cell lines undergoing antineoplastic treatment, has previously been demonstrated for both **PA** and **VPA**,<sup>75,76</sup> the effect of Pt(IV) derivatives included in this study on the







distribution of HCT116, HCT8, RKO and HT29 cell lines in the different phases of the cell cycle was evaluated.

Cell-type differences were also observed in the results obtained in this set of experiments (Fig. 2). In particular, none of the Pt(IV) and reference compounds was able to induce cell cycle alterations in HT29 cells, while the cell cycle shift was variable in the other three cell lines. This different behavior could also be related to the status of p53. According to data from other authors,<sup>75,76</sup> when cell cycle alterations were present, a shift toward the G0/G1 phase and a corresponding reduction in the S phase was observed.

Cell cycle progression is finely regulated by the inhibitory activity of a family of proteins capable of binding to specific protein kinase complexes, which are responsible for the passage of cells through the different phases of the cell cycle. In particular, p21<sup>waf1/cip1</sup>, a member of the Cip/Kip family, is known to play a critical role in the regulation of the cellular transition in the G1/S phase and alteration in its protein levels could explain the results shown in Fig. 2. Thus, the effect of the equitoxic concentrations of 4, 5, 6, 7, 9, PA, VPA, and oxaliplatin on p21<sup>waf1/cip1</sup> protein levels was evaluated. Fig. 3 shows that all the compounds studied induced an increase in p21<sup>waf1/cip1</sup> levels, although to different extents. In particular, in HCT116 cells, the G1/G0 shift and the consequent lower percentage of apoptotic cells observed following treatment with 7 could be related to a greater increase in p21<sup>waf1/cip1</sup> induced by this compound. As a confirmation, the low increase in p21<sup>waf1/cip1</sup> protein levels shown in the same cell line after treatment with 5 and 9 did not lead to cell cycle alterations or to a reduced apoptotic response. On the other hand, in RKO cells, a high increase in p21<sup>waf1/cip1</sup> following treatment with all Pt(IV) derivatives led to a G0/G1 shift and high levels of apoptosis. Furthermore, HT29 cells increased p21<sup>waf1/cip1</sup> levels once treated with 4, 5, 6, 7, 9, PA, VPA, and oxaliplatin; however, no cell cycle alterations were observed. Therefore, p21<sup>waf1/cip1</sup> may play a role in the response to Pt(IV) derivatives; however, other factors are probably involved.



**Fig. 2** Effects on cell cycle progression. Cells were exposed for 72 h to oxaliplatin (oxPt), PA, VPA, and different Pt(IV) derivatives at equitoxic concentrations corresponding to the respective IC<sub>50</sub> values (mean  $\pm$  S.E. of three independent experiments).



**Fig. 3** Western blot analysis of p21<sup>waf1/cip1</sup> levels in HCT116, HCT8, RKO, and HT29 cell lines treated 72 h with oxaliplatin (oxPt), PA, VPA and the different Pt(IV) derivatives studied at equitoxic concentrations corresponding to the respective IC<sub>50</sub> values (mean  $\pm$  S.E. of three independent experiments).

### Effects on histone deacetylases

Experimental evidence indicates that VPA-containing Pt(IV) derivatives possess both the DNA binding activity, typical of the Pt(II) derivatives, and the histone deacetylase (HDAC) inhibitory activity of VPA.<sup>14,15,34,35,80,81</sup> The latter directly inhibits HDAC, inducing hyperacetylation of histones H3 and H4 *in vivo* and *in vitro*<sup>82,83</sup> and thereby increasing the accessibility of DNA within chromatin to DNA-binding agents, such as cisplatin and its derivatives.<sup>35,84</sup> Furthermore, in addition to their epigenetic effects, HDAC inhibitors are known to play pivotal roles in non-epigenetic regulation, cell cycle arrest, and apoptosis.<sup>77</sup>


To evaluate the possible effects of 4, 5, 6, 7, 9 and reference compounds on histone deacetylase activity, a western blot analysis was performed to evaluate the acetylated histone H3 and H4 proteins in HCT116, HCT8, RKO, and HT29 cell lines after 72 h of treatment with the compounds at concentrations corresponding to the respective IC<sub>50</sub> values.

As expected, VPA was able to inhibit HDAC, leading to a significant increase in acetylated H3 and H4 histones (Fig. 4A and B), while PA showed limited effects on HDAC inhibition through a statistically significant increase in histone H4 acetylation, but only in HCT116 cells. Furthermore, in HCT116, HCT8 and RKO cell lines, only the Pt(IV) derivatives containing VPA in their molecule, namely 5, 7, and 9, were able to induce significant increases in the acetylated histones H3 and H4, the index of the inhibition of HDAC, at levels similar to those obtained following treatment with VPA alone, but of course at a considerably lower concentration. Conversely, in HT29 cells only following treatment with 5, it was possible to observe an increase in the acetylated histone protein levels; however, this increase was limited to H3.

### Effects on cellular migration

Degradation of the extracellular matrix and the basal membrane is the first step toward migration and invasion. Matrix metalloproteinases (MMPs) and their tissue inhibitors modulate these processes. Thus, higher expression of different MMPs facilitates invasion and metastasis, as evidenced in a number of human cancers.<sup>85,86</sup>






**Fig. 4** Acetylated histones H3 (A) and H4 (B) in HCT116, HCT8, RKO and HT29 cell lines treated for 72 h with the studied compounds at concentrations corresponding to the respective  $IC_{50}$  values (oxPt = oxaliplatin). The graphs represent the densitometric analysis of three independent western blot experiments. Statistical analysis: \* $p < 0.05$ , \*\* $p < 0.01$  and \*\*\* $p < 0.001$  vs. control (C).

In this context, a Pt(IV) derivative containing **PA** has previously been reported to reduce the invasiveness of a lung cancer cell line,<sup>50</sup> while other authors have shown that **PA** administration decreased the metastatic potential of melanoma cells *in vivo*.<sup>47</sup> In both cases, MMP2 (gelatinase-A) and MMP9 (gelatinase-B) were associated with these effects. Interestingly, recently it has been reported that **VPA** has also shown antimigratory effects in a chicken embryo chorioallantoic membrane model.<sup>87</sup> Therefore, to test if the Pt(IV) derivatives could reduce MMP protein levels, thus inhibiting cellular migration, a western blot analysis was performed on total colon cancer lysates to evaluate MMP2 and MMP9 protein levels, after 72 h treatment with the equitoxic concentrations of **4**, **5**, **6**, **7**, **9** and reference compounds (Fig. 5).

In general, oxaliplatin, **PA** and **VPA** showed variable inhibitory effects on MMP2 and MMP9 levels in the different cell lines. In particular, oxaliplatin statistically reduced MMP2 in HT8, **PA** in HCT116 and RKO, and **VPA** in RKO cells. For MMP9, a statistically significant reduction in the protein level was observed for oxaliplatin in RKO, for **PA** in HT8 and RKO,



**Fig. 5** MMP2 and MMP9 protein levels (representative western blot analysis out of three independent experiments with similar results) in HCT116, HCT8, RKO and HT29 cell lines treated 72 h with **4**, **5**, **6**, **7**, **9**, oxaliplatin (oxPt), **PA**, and **VPA** at equitoxic concentrations corresponding to the respective  $IC_{50}$  values and relative densitometric analysis performed on all western blot experiments. Statistical analysis: \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$  vs. control (C).

and for **VPA** in HCT116 and RKO. No alterations in the protein levels of the considered metalloproteinases were observed in HT29 treated with oxaliplatin, **PA**, and **VPA**.

When the effects of the Pt(IV) derivatives on the levels of the MMP2 and MMP9 proteins were evaluated, **4**, **5**, **6**, **7** and **9** significantly reduced the MMP2 levels in all four cell lines. Regarding MMP9, a significant reduction in this metalloproteinase was observed, compared to control levels, in HCT116



treated with **6**, HCT8 cells treated with **5**, **6**, **7** and **9** and RKO cells treated with all compounds. Similar to the case of the reference compounds, no decreases in both MMP2 and MMP9 protein levels were observed in HT29 cells after treatment with Pt(IV) derivatives.

The observed general lack of effects of the Pt(IV) derivatives on the MMP2 and MMP9 protein levels in HT29 could be explained, once again, considering the p53 status of this cell line. Actually, the loss of the p53 function has been reported to enhance invasion and metastasis through MMP production and activation of several survival pathways and it has been reported that the restoration of the p53 function could decrease the activity of MMPs.<sup>88,89</sup>

## Experimental section

### General procedures

All chemicals (Sigma Aldrich-Merck or Alfa Aesar-Thermo Fisher Scientific, except where otherwise specified) were used as received and without further purification. Complexes (*SP-4-2*)-dichlorido(cyclohexane-1*R*,2*R*-diamine)platinum(II) ([PtCl<sub>2</sub>(dach)] (**1**),<sup>51,90</sup> (*OC-6-44*)-acetatodichlorido(cyclohexane-1*R*,2*R*-diamine)hydroxidoplatinum(IV) (**2**)<sup>54</sup> and (*OC-6-33*)-dichlorido(cyclohexane-1*R*,2*R*-diamine)dihydroxidoplatinum(IV) (**3**),<sup>64</sup> and the acyl chloride of perillic acid (**PA**)<sup>74</sup> were prepared according to published procedures.

Microwave-assisted synthesis was performed using a CEM Discover® SP System equipped with a focused single-mode and self-tuning cavity, an air-cooling system, and an automated power control based on temperature feedback, supplying power in 1 W increments from 0 to 300 W.

The purity of all the compounds was assessed using an analytical RP-HPLC (≥98%). Chromatographic analysis and purifications were carried out using a C18 Phenomenex PhenoSphere-NEXT (5 μm, 250 × 4.6 mm ID) column on a Waters HPLC-MS instrument (equipped with an Alliance 2695 separation module, a 2487 dual lambda absorbance detector and a 3100 mass detector) with a 70/30 v/v mixture of methanol/15 mM aqueous formic acid as the mobile phase. The flow was set at 0.500 mL min<sup>-1</sup> and the wavelength of the UV-vis detector was set at 210 nm.

The MS spectra were recorded using source and desolvation temperatures set at 150 and 250 °C, respectively, with nitrogen used both as a drying gas and as a nebulizing gas. The cone and capillary voltages were usually +30 V (positive ion mode) and 2.70 kV, respectively. Quasi-molecular ion peaks [M + H]<sup>+</sup> were assigned on the basis of the *m/z* values and the simulated isotope distribution patterns.

The NMR spectra were measured on an NMR-Bruker Avance III operating at 500 MHz (<sup>1</sup>H), 125.7 MHz (<sup>13</sup>C), and 107.2 MHz (<sup>195</sup>Pt), respectively. <sup>1</sup>H and <sup>13</sup>C NMR chemical shifts were referenced to solvent resonances, whereas for <sup>195</sup>Pt NMR signals, a solution of K<sub>2</sub>[PtCl<sub>4</sub>] in saturated aqueous KCl was used as an external reference (δ = -1628 ppm). The num-

bering scheme for the assignment of NMR signals is reported in Scheme S1 (see the ESI†).

### Microwave-assisted synthesis of complexes 4–7

A solution of the acyl chloride of perillic acid (**PA**)<sup>74</sup> (0.101 g, 0.548 mmol for **4** or 0.056 g, 0.302 mmol for **6**) or a solution of the commercially available acyl chloride of **VPA** (96 μL, 0.548 mmol for **5** or 105 μL, 0.598 mmol for **7**) in anhydrous acetonitrile (about 2 mL) was added in a microwave vessel to a suspension of complex **2** (0.050 g, 0.110 mmol for **4** and **5**) or complex **3** (0.050 g, 0.121 mmol for **6** and **7**) in anhydrous acetonitrile (about 2 mL). Excess pyridine (40 μL) was added dropwise to the reaction mixture under stirring and the vessel was capped and introduced into the microwave cavity. The microwave unit was programmed to heat the mixture to 55 °C over a 5 min ramp period and then maintain it at this temperature for 1 hour under stirring; the power was automatically set at 50 W. After it was heated, the vessel was allowed to cool to room temperature before being removed from the cavity. After filtering the mixture (0.45 μm PTFE filter), the resulting solution was transferred into a 25 mL round-bottom flask and dried with a rotary evaporator. The resulting oil was treated with hexane and then with water at least three times to produce a pale-yellow to pale-brown powder.

**4.** Yield: 0.035 g, 53%. ESI-MS (positive ion mode): 605 *m/z*; calcd for C<sub>18</sub>H<sub>31</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>4</sub>Pt [M + H]<sup>+</sup>: 605 *m/z*. <sup>1</sup>H NMR (500.13 MHz, DMSO-*d*<sub>6</sub>): δ 1.13 (m, 2H, H16 and H17), 1.32–1.36 (m, 3H, H8, H15 and H18), 1.50–1.52 (m, 2H, H16' and H17'), 1.71 (m, 3H, H12), 1.76–1.78 (m, 1H, H8'), 1.96 (s, 3H, H1), 2.07 (m, 1H, H6), 2.09 (m, 1H, H7), 2.11 (m, 1H, H9), 2.19–2.21 (m, 2H, H15' and H18'), 2.24 (m, 1H, H6'), 2.33–2.36 (m, 1H, H9'), 2.50–2.55 (m, 2H, H13 and H14), 4.72 (m, 2H, H11), 6.75 (m, 1H, H5), 8.19–9.53 (m, 4H, -NH<sub>2</sub>) ppm. <sup>13</sup>C NMR (125.76 MHz, DMSO-*d*<sub>6</sub>): δ 20.5 (C12), 23.4 (C16 and C17), 23.5 (C1), 24.9 (C9), 26.8 (C8), 30.3 (C6), 31.1–31.2 (C15 and C18), 40.0 (C7), 62.6 (C13 and C14), 109.1 (C11), 132.2 (C4), 137.1 (C5), 148.7 (C10), 176.7 (C3), 180.7 (C2) ppm. <sup>195</sup>Pt NMR (107.51 MHz, DMSO-*d*<sub>6</sub>): δ 1088 ppm.

**5.** Yield: 0.014 g, 22%. ESI-MS (positive ion mode): 583 *m/z*; calcd for C<sub>16</sub>H<sub>33</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>4</sub>Pt [M + H]<sup>+</sup>: 583 *m/z*. <sup>1</sup>H NMR (500.13 MHz, DMSO-*d*<sub>6</sub>): δ 0.84 (m, 6H, H13), 0.97–1.16 (m, 2H, H3 and H4), 1.24–1.34 (m, 8H, H11, H12, H2 and H5), 1.36–1.56 (m, 6H, H11', H3' and H4'), 1.95 (2, 3H, H8), 2.18–2.28 (m, 3H, H10, H2' and H5'), 2.36–2.63 (m, 2H, H1 and H6), 8.15–9.67 (m, 4H, -NH<sub>2</sub>) ppm. <sup>13</sup>C NMR (125.76 MHz, DMSO-*d*<sub>6</sub>): δ 13.99–14.04 (C13), 19.9–20.1 (C12), 23.4–23.6–23.7 (C3, C4 and C8), 31.0–31.4 (C2 and C5), 34.6–34.8 (C11), 46.9 (C10), 62.1–63.1 (C1 and C6), 180.8 (C7), 186.0 (C9) ppm. <sup>195</sup>Pt NMR (107.51 MHz, DMSO-*d*<sub>6</sub>): δ 1113 ppm.

**6.** Yield: 0.036 g, 42%. ESI-MS (positive ion mode): 711 *m/z*; calcd for C<sub>26</sub>H<sub>41</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>4</sub>Pt [M + H]<sup>+</sup>: 711 *m/z*. <sup>1</sup>H NMR (500.13 MHz, DMSO-*d*<sub>6</sub>): δ 1.12 (m, 2H, H16 and H17), 1.34–1.36 (m, 4H, H8, H15 and H18), 1.50–1.52 (m, 2H, H16' and H17'), 1.71 (m, 6H, H12), 1.76–1.78 (m, 2H, H8'), 2.04–2.09 (m, 6H, H6, H7 and H9), 2.20–2.23 (m, 2H, H15' and



H18'), 2.27 (m, 2H, H6'), 2.34–2.37 (m, 2H, H9'), 2.55 (m, 2H, H13 and H14), 4.72 (m, 4H, H11), 6.75 (m, 2H, H5), 8.22–9.56 (m, 4H,  $-NH_2$ ) ppm.  $^{13}C$  NMR (125.76 MHz, DMSO- $d_6$ ):  $\delta$  20.5 (C12), 23.4 (C16 and C17), 24.9 (C9), 26.8 (C8), 30.3 (C6), 31.2 (C15 and C18), 40.0 (C7), 62.7 (C13 and C14), 109.1 (C11), 132.2 (C4), 137.1 (C5), 148.7 (C10), 176.7 (C3) ppm.  $^{195}Pt$  NMR (107.51 MHz, DMSO- $d_6$ ):  $\delta$  1072 ppm.

7. Yield: 0.019 g, 23%. ESI-MS (positive ion mode): 667  $m/z$ ; calcd for  $C_{22}H_{45}Cl_2N_2O_4Pt$   $[M + H]^+$ : 667  $m/z$ .  $^1H$  NMR (500.13 MHz, DMSO- $d_6$ ):  $\delta$  0.85 (m, 12H, H11), 1.02 (m, 2H, H3 and H4), 1.27 (m, 14H, H9, H10, H2 and H5), 1.47 (m, 4H, H9'), 1.56 (m, 2H, H3' and H4'), 2.21–2.30 (m, 4H, H8, H2' and H5'), 2.45 (m, 2H, H1 and H6), 8.20 and 9.66 (m, 4H,  $-NH_2$ ) ppm.  $^{13}C$  NMR (125.76 MHz, DMSO- $d_6$ ):  $\delta$  14.0–14.1 (C11), 20.0–20.1 (C10), 23.7 (C3 and C4), 31.4 (C2 and C5), 34.6–34.8 (C9), 46.9 (C8), 62.7 (C1 and C6), 186.1 (C7) ppm.  $^{195}Pt$  NMR (107.51 MHz, DMSO- $d_6$ ):  $\delta$  1106 ppm.

### Synthesis of complex 8

Complex 8 was prepared by modifying synthetic procedures employed to prepare other unsymmetric Pt(IV) complexes,<sup>91</sup> as follows.

**Synthesis of perillic anhydride.** Perillic acid (0.300 g, 1.80 mmol) was dissolved in 10 mL of anhydrous dichloromethane and then *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride (0.173 g, 0.902 mmol) was added. The mixture reacted at room temperature under stirring for 24 hours. The resulting colorless solution was washed with 3% aqueous citric acid, then with 3% aqueous sodium hydrogen carbonate, and finally with 3% aqueous sodium chloride. After treatment with anhydrous sodium sulfate, the organic phase was dried by means of a rotary evaporator to get a colorless liquid. The product was then used as it was, considering a quantitative yield.

**Synthesis of complex 8.** Under stirring, complex 3 (0.050 g, 0.121 mmol) was suspended in a solution of perillic anhydride in 15 mL of DMSO. The mixture was left to react at 65 °C, in the dark, for 24 hours. Over this time, the initial pale-yellow suspension turned into a pale brown suspension, which was then dried by means of a rotary evaporator. The resulting brown oil was dissolved in acetonitrile and the addition of diethyl ether allowed for the precipitation of the crude product after 4 h in a refrigerator (43% purity). The powdery dove-colored product was isolated by centrifugation and dissolved in methanol. The solution was centrifuged to remove solid impurities and then dried with the rotary evaporator. The residue was washed several times with water and then dissolved in methanol, and the solution was centrifuged to remove impurities again. The supernatant was dried with the rotary evaporator, washed with diethyl ether, and dried under a nitrogen flow (yield: 0.008 g, 12%). ESI MS (positive ion mode): 563  $m/z$ ; calcd for  $C_{16}H_{29}Cl_2N_2O_3Pt$   $[M + H]^+$ : 563  $m/z$ .  $^1H$  NMR (500.13 MHz, DMSO- $d_6$ ):  $\delta$  1.05 (m, 2H, H3 and H4), 1.31 (m, 3H, H2, H5 and H10), 1.49 (m, 3H, H3', H4' and H10'), 1.71 (s, 3H, H15), 1.76 (m, 2H, H2' and H5'), 2.05 (m, 3H, H9, H11, H12), 2.19 (m, 1H, H12'), 2.34 (m, 1H, H9'),

2.50–2.65 (m, 2H, H1 and H6), 4.71 (m, 2H, H16), 6.68 (m, 1H, H13), 7.04–9.51 (m, 4H,  $-NH_2$ ) ppm.  $^{13}C$  NMR (125.76 MHz, DMSO- $d_6$ ):  $\delta$  20.6 (C15), 23.7 (C3 and C4), 25.1 (C9), 27.0 (C2 and C5), 30.3 (C12), 30.7 (C10), 40.0 (C11), 60.9 and 62.9 (C1 and C6), 109.1 (C16), 133.8 (C8), 135.4 (C13), 148.9 (C14), 176.8 (C7) ppm.  $^{195}Pt$  NMR (107.51 MHz, DMSO- $d_6$ ):  $\delta$  903 ppm.

### Microwave-assisted synthesis of complex 9

A solution of the commercial acyl chloride of VPA (62  $\mu$ L, 0.356 mmol) in anhydrous acetonitrile (2 mL) was added in a microwave vessel to a suspension of complex 8 (0.040 g, 0.071 mmol) in the same solvent (2 mL). Excess pyridine (40  $\mu$ L) was added dropwise to the stirring reaction mixture and the vessel was capped and introduced into the microwave cavity. The microwave unit was programmed to heat the vessel content to 55 °C over a 5 min ramp period and then maintained it at this temperature for 1 hour under stirring; the power was automatically set at 50 W. After heating, the vessel was allowed to cool to room temperature before removing it from the cavity. The solution obtained was transferred into a round-bottom flask and dried with the rotary evaporator. The resulting oil was treated with hexane and then water to yield a beige powder (yield: 0.026 g, 53%). ESI-MS (positive ion mode): 689  $m/z$ ; calcd for  $C_{24}H_{43}Cl_2N_2O_4Pt$   $[M + H]^+$ : 689  $m/z$ .  $^1H$  NMR (500.13 MHz, DMSO- $d_6$ ):  $\delta$  0.85 (m, 6H, H21), 0.98–1.18 (m, 2H, H3 and H4), 1.24–1.41 (m, 9H, H2, H5, H10, H19 and H20), 1.43–1.57 (m, 4H, H19', H3' and H4'), 1.71 (s, 3H, H15), 1.73–1.79 (m, 1H, H10'), 2.02–2.11 (m, 3H, H9, H11, H12), 2.19–2.30 (m, 4H, H18, H12, H2' and H5'), 2.36 (m, 1H, H9'), 2.43–2.63 (m, 2H, H1 and H6), 4.72 (m, 2H, H16), 6.75 (m, 1H, H13), 8.19–9.70 (m, 4H,  $-NH_2$ ) ppm.  $^{13}C$  NMR (125.76 MHz, DMSO- $d_6$ ):  $\delta$  14.5–14.6 (C21), 20.5–20.6 (C20), 21.1 (C15), 23.9–24.3 (C3 and C4), 25.5 (C9), 27.4 (C10), 30.8 (C12), 31.1–31.4 (C2 and C5), 35.1–35.3 (C19), 40.0 (C11), 47.4 (C18), 62.7–63.7 (C1 and C6), 109.7 (C16), 132.8 (C8), 137.5 (C13), 149.2 (C14), 177.2 (C7), 186.5 (C17) ppm.  $^{195}Pt$  NMR (107.51 MHz, DMSO- $d_6$ ):  $\delta$  1097 ppm.

### Lipophilicity

RP-HPLC was used to measure the capacity factors  $k'$  of the compounds as previously reported.<sup>69</sup> Briefly, a chromatogram for each compound was recorded on a C18 column PhenoSphere-NEXT (5  $\mu$ m, 250  $\times$  4.6 mm internal diameter) with eluent composition of 15 mM formic acid 30% v/v in CH<sub>3</sub>OH and a flow of 0.5 mL min<sup>−1</sup>. The corresponding retention time  $t_R$  was converted into log  $k'$ , where  $k' = (t_R - t_0)/t_0$ . The dead time of the column  $t_0$  was the  $t_R$  of reference KCl.

### Cell culture and viability assay

Human colon carcinoma cell lines HCT116, RKO, HCT8 and HT29 were obtained from ATCC (American Type Culture Collection, Manassas, VA, USA) and maintained in the DMEM (Euroclone, Milan, Italy), supplemented with 10% fetal calf serum (Euroclone, Milan, Italy), a 1% glutamine and 1% antibiotic mixture, 1% sodium pyruvate and 1% non-essential





amino acids (both Sigma-Aldrich, Milan, Italy) at 37 °C under a humidified 5% CO<sub>2</sub> atmosphere. Cells were routinely checked for *Mycoplasma* (Molecular Biology Reagent Set Mycoplasma Species, Euroclone, UK). For all experiments, cells were exposed to the different Pt(IV) derivatives tested and to the reference compounds **1**, oxaliplatin, valproic acid, and perillic acid for 72 h. When DMSO was used as a solvent, the final concentration never exceeded 0.1% v/v. This concentration was found to be non-toxic to the cells tested (control). The effect of all derivatives on cellular viability was assessed using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, according to previously published procedures. Briefly,  $3 \times 10^3$  cells were seeded in 96-well plates and allowed to attach for 24 h. The cells were then treated for 72 h with growing concentrations (**1**, **4**, **5**, **6**, **7**, **9**, and oxaliplatin: from 10 up to 1000 nM; **PA** and **VPA**: from 10 to 500 µM) of the compounds studied. At the end of the incubation period, MTT (0.05 mL of a 2 mg mL<sup>-1</sup> stock solution in PBS) was added to each well and cells were incubated for 3 h at 37 °C. Cell viability was determined by measuring the absorbance of the DMSO-dissolved blue formazan crystals ( $\lambda = 570$  nm), formed through MTT reduction by metabolically active cells, in individual wells, using an iMARK Microplate Reader (Bio-RAD). IC<sub>50</sub> values were calculated based on the nonlinear regression analysis of dose–response data performed with CalcuSyn software (Biosoft, Cambridge, UK). Differences between IC<sub>50</sub> values were statistically evaluated by analysis of variance with the Bonferroni post-test for multiple comparisons.

### Western blot analysis

The levels of the H3, H4, MMP2 and MMP9, and p21 proteins in whole cell lysates following 72 h treatment with the compounds under investigation at concentrations corresponding to the respective IC<sub>50</sub> were detected by western blot analysis. For whole cell lysates, cells were resuspended in lysis buffer (NaCl 120 mM, NaF 25 mM, EDTA 5 mM, EGTA 6 mM, sodium pyrophosphate 25 mM in Tris-buffered saline TBS 20 mM at pH 7.4, phenylmethanesulfonyl fluoride 2 mM, Na<sub>3</sub>VO<sub>4</sub> 1 mM, phenylarsine oxide 1 mM, 1% NP-40 and 10% protease inhibitor cocktail) and incubated for 10 min on ice after adding Nonidet P-40 (final concentration 0.1%) and lysates were collected by centrifugation (12 800 rpm for 20 min). The protein concentration was determined by a BCA assay (Pierce, Italy) and 50 µg of protein per sample were loaded onto 8% polyacrylamide gels and separated under denaturing conditions. Protein bands were then transferred to Hybond-P membranes (Amersham Biosciences, Italy) and western blot analysis was performed using standard techniques with mouse monoclonal antibodies directed against human MMP2, MMP9, H3, H4 and p21 (Santa Cruz Biotechnology, Inc). Equal loading of the samples was verified by re-probing the blots with a mouse monoclonal anti-β-actin antibody (Santa Cruz Biotechnology, Inc.). Protein bands were visualized using a G-box (Syngene, Chemi-Xt4) using peroxidase-conjugated anti-mouse secondary antibodies (Sigma-Aldrich) and a Westar Supernova Substrate (Cyanagen). Densitometric analysis was performed

using Image-J software and differences between obtained values were evaluated by analysis of variance with the Bonferroni post-test for multiple comparisons.

### Cell death induction and cell cycle analysis

The ability of the Pt(IV) derivatives tested to induce apoptotic and/or necrotic cell death and/or alterations in the distribution of DNA through the cell cycle was evaluated by flow cytometric analysis following 72 h exposure of the cells at concentrations corresponding to the IC<sub>50</sub> values. At the end of the treatment, cells were detached, washed in PBS and fixed in 70% ethanol at –20 °C and after a further wash in PBS, DNA was stained with a solution of PI in PBS (50 µg mL<sup>-1</sup>) in the presence of RNase A (30 U mL<sup>-1</sup>) at room temperature for 15 min before analyzing the samples. To determine the percentage of necrotic cells, the fixation step was omitted. The fluorescence emission of PI was collected through a 575 nm band-pass filter using a FACSCalibur (Becton Dickinson) and the percentage of apoptotic cells in each sample was determined based on the sub-G1 peaks detected in mono-parametric histograms acquired in the log mode, while the DNA distribution through the different phases of the cell cycle was determined on peaks acquired in the linear mode. The percentage of necrotic cells was assessed by the increase of PI fluorescence histograms acquired in the log mode.

## Conclusions

Multitarget Pt(IV) combos represent an interesting (and we dare say not a red herring) chemotherapeutic alternative, allowing the association between the cytotoxic effects of Pt-based drugs and the effects of axial bioactive ligands to improve selectivity and efficacy, and also exploiting the peculiar characteristics of the oxidized Pt(IV) center (activation by reduction).<sup>6,9–13,92,93</sup>

In the present article, a colon-oriented Pt moiety containing the dach ligand, the HDACi properties of valproic acid, and the potential antimetastatic efficacy of perillic acid were combined for the first time. The results indicate that it is relatively easy to obtain Pt(IV) combos operating at the nanomolar scale and hence they are more potent than the reference compounds or the single fragments. However, this was not simply obtained by increasing the lipophilicity of the compounds. Actually, the synthesized complexes possess pro-apoptotic and pro-necrotic properties and the ability to induce cell cycle alterations. Furthermore, they were able to downregulate HDAC activity, leading to an increase in the histone H3 and H4 levels. Finally, they exerted antimigratory activity by reducing the levels of the MMP2 and MMP9 proteins. All these activities, along with the alkylating effect of [PtCl<sub>2</sub>(dach)], are probably related to a synergistic cellular accumulation of the Pt moiety, **VPA** and **PA**, leading to a higher intracellular concentration of these three compounds, compared to the concentrations obtained after co-administration of the three free compounds. Importantly, as a demonstration, the Pt(IV) complexes showed biological



properties similar to or better than those of VPA and PA but at lower concentrations.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The figure of the table of content was partly generated using Servier Medical Art, provided by Servier, licensed under a Creative Commons Attribution 3.0 Unported license (<https://creativecommons.org/licenses/by/3.0/>).

## References

- 1 E. Wexselblatt and D. Gibson, *J. Inorg. Biochem.*, 2012, **117**, 220–229.
- 2 D. Gibson, *Dalton Trans.*, 2016, **45**, 12983–12991.
- 3 D. Gibson, *ChemMedChem*, 2021, **16**, 2188–2191.
- 4 D. Gibson, *J. Inorg. Biochem.*, 2021, **217**, 111353.
- 5 M. Ravera, E. Gabano, M. J. McGlinchey and D. Osella, *Dalton Trans.*, 2022, **51**, 2121–2134.
- 6 Z. Xu, Z. Wang, Z. Deng and G. Zhu, *Coord. Chem. Rev.*, 2021, **442**, 213991.
- 7 X. Y. Wang and Z. J. Guo, *Chem. Soc. Rev.*, 2013, **42**, 202–224.
- 8 J. S. Butler and P. J. Sadler, *Curr. Opin. Chem. Biol.*, 2013, **17**, 175–188.
- 9 E. Gabano, M. Ravera and D. Osella, *Dalton Trans.*, 2014, **43**, 9813–9820.
- 10 R. G. Kenny, S. W. Chuah, A. Crawford and C. J. Marmion, *Eur. J. Inorg. Chem.*, 2017, 1596–1612.
- 11 R. G. Kenny and C. J. Marmion, *Chem. Rev.*, 2019, **119**, 1058–1137.
- 12 M. Ravera, E. Gabano, M. J. McGlinchey and D. Osella, *Inorg. Chim. Acta*, 2019, **492**, 32–47.
- 13 C. Y. Jia, G. B. Deacon, Y. J. Zhang and C. Z. Gao, *Coord. Chem. Rev.*, 2021, **429**, 213640.
- 14 R. Raveendran, J. P. Braude, E. Wexselblatt, V. Novohradsky, O. Stuchlikova, V. Brabec, V. Gandin and D. Gibson, *Chem. Sci.*, 2016, **7**, 2381–2391.
- 15 V. Novohradsky, L. Zerzankova, J. Stepankova, O. Vrana, R. Raveendran, D. Gibson, J. Kasparkova and V. Brabec, *Biochem. Pharmacol.*, 2015, **95**, 133–144.
- 16 E. D. Scheeff, J. M. Briggs and S. B. Howell, *Mol. Pharmacol.*, 1999, **56**, 633–643.
- 17 K. Gkionis, S. T. Mutter and J. A. Platts, *RSC Adv.*, 2013, **3**, 4066–4073.
- 18 A. M. Di Francesco, A. Ruggiero and R. Riccardi, *Cell. Mol. Life Sci.*, 2002, **59**, 1914–1927.
- 19 F. Arnesano, A. Pannunzio, M. Coluccia and G. Natile, *Coord. Chem. Rev.*, 2015, **284**, 286–297.
- 20 M. Sabbatini, I. Zanellato, M. Ravera, E. Gabano, E. Perin, B. Rangone and D. Osella, *J. Med. Chem.*, 2019, **62**, 3395–3406.
- 21 A. Kastner, T. Mendrina, F. Bachmann, W. Berger, B. K. Keppler, P. Heffeter and C. R. Kowol, *Inorg. Chem. Front.*, 2023, **10**, 4126–4138.
- 22 E. Wexselblatt, E. Yavin and D. Gibson, *Angew. Chem., Int. Ed.*, 2013, **52**, 6059–6062.
- 23 M. Ravera, E. Gabano, S. Bianco, G. Ermondi, G. Caron, M. Vallaro, G. Pelosi, I. Zanellato, I. Bonarrigo, C. Cassino and D. Osella, *Inorg. Chim. Acta*, 2015, **432**, 115–127.
- 24 S. Minucci and P. G. Pelicci, *Nat. Rev. Cancer*, 2006, **6**, 38–51.
- 25 J. E. Bolden, M. J. Peart and R. W. Johnstone, *Nat. Rev. Drug Discovery*, 2006, **5**, 769–784.
- 26 D. Morel, D. Jeffery, S. Aspeslagh, G. Almouzni and S. Postel-Vinay, *Nat. Rev. Clin. Oncol.*, 2020, **17**, 91–107.
- 27 R. Roy, T. Ria, D. RoyMahaPatra and U. H. Sk, *ACS Omega*, 2023, **8**, 16532–16544.
- 28 K. J. Falkenberg and R. W. Johnstone, *Nat. Rev. Drug Discovery*, 2014, **13**, 673–691.
- 29 J. Roche and P. Bertrand, *Eur. J. Med. Chem.*, 2016, **121**, 451–483.
- 30 T. Eckschlager, J. Plch, M. Stiborova and J. Hrabeta, *Int. J. Mol. Sci.*, 2017, **18**, 1414.
- 31 A. Suraweera, K. J. O'Byrne and D. J. Richard, *Front. Oncol.*, 2018, **8**, 15.
- 32 A. D. Bondarev, M. M. Attwood, J. Jonsson, V. N. Chubarev, V. V. Tarasov and H. B. Schioth, *Br. J. Clin. Pharmacol.*, 2021, **87**, 4577–4597.
- 33 J. Yang, X. Sun, W. Mao, M. Sui, J. Tang and Y. Shen, *Mol. Pharm.*, 2012, **9**, 2793–2800.
- 34 M. Alessio, I. Zanellato, I. Bonarrigo, E. Gabano, M. Ravera and D. Osella, *J. Inorg. Biochem.*, 2013, **129**, 52–57.
- 35 V. Novohradsky, L. Zerzankova, J. Stepankova, O. Vrana, R. Raveendran, D. Gibson, J. Kasparkova and V. Brabec, *J. Inorg. Biochem.*, 2014, **140**, 72–79.
- 36 A. R. Z. Almotairy, V. Gandin, L. Morrison, C. Marzano, D. Montagner and A. Erxleben, *J. Inorg. Biochem.*, 2017, **177**, 1–7.
- 37 M. Ravera, E. Gabano, I. Zanellato, A. Gallina, E. Perin, A. Arrais, S. Cantamessa and D. Osella, *Dalton Trans.*, 2017, **46**, 1559–1566.
- 38 E. Gabano, M. Ravera, I. Zanellato, S. Tinello, A. Gallina, B. Rangone, V. Gandin, C. Marzano, M. G. Bottone and D. Osella, *Dalton Trans.*, 2017, **46**, 14174–14185.
- 39 B. Rangone, B. Ferrari, V. Astesana, I. Masiello, P. Veneroni, I. Zanellato, D. Osella and M. G. Bottone, *Life Sci.*, 2018, **210**, 166–176.
- 40 E. Gabano, B. Rangone, E. Perin, G. Caron, G. Ermondi, M. Vallaro, V. Gandin, C. Marzano, A. Barbanente, N. Margiotta and M. Ravera, *Dalton Trans.*, 2021, **50**, 4663–4672.
- 41 M. H. Gelb, F. Tamanoi, K. Yokoyama, F. Ghomashchi, K. Esson and M. N. Gould, *Cancer Lett.*, 1995, **91**, 169–175.



- 42 Y. Pylayeva-Gupta, E. Grabocka and D. Bar-Sagi, *Nat. Rev. Cancer*, 2011, **11**, 761–774.
- 43 N. Berndt, A. D. Hamilton and S. M. Sebt, *Nat. Rev. Cancer*, 2011, **11**, 775–791.
- 44 H. van Hattum and H. Waldmann, *Chem. Biol.*, 2014, **21**, 1185–1195.
- 45 A. D. Cox, C. J. Der and M. R. Philips, *Clin. Cancer Res.*, 2015, **21**, 1819–1827.
- 46 X. D. Zhao and S. Subramanian, *Pharmacol. Ther.*, 2018, **181**, 76–84.
- 47 T. J. Raphael and G. Kuttan, *J. Exp. Clin. Cancer Res.*, 2003, **22**, 419–424.
- 48 T. J. Raphael and G. Kuttan, *Immunopharmacol. Immunotoxicol.*, 2003, **25**, 285–294.
- 49 D. Samaila, B. J. Toy, R. C. Wang and J. A. Elegbede, *Anticancer Res.*, 2004, **24**, 3089–3095.
- 50 M. Ravera, E. Gabano, I. Zanellato, B. Rangone, E. Perin, B. Ferrari, M. G. Bottone and D. Osella, *Dalton Trans.*, 2021, **50**, 3161–3177.
- 51 S. C. Dhara, *Indian J. Chem.*, 1970, **8**, 193–194.
- 52 F. D. Rochon and L. M. Gruia, *Inorg. Chim. Acta*, 2000, **306**, 193–204.
- 53 J. Z. Zhang, P. Bonnitche, E. Wexselblatt, A. V. Klein, Y. Najajreh, D. Gibson and T. W. Hambley, *Chem. – Eur. J.*, 2013, **19**, 1672–1676.
- 54 E. Gabano, M. Ravera, E. Perin, I. Zanellato, B. Rangone, M. J. McGlinchey and D. Osella, *Dalton Trans.*, 2019, **48**, 435–445.
- 55 E. Gabano and M. Ravera, *Molecules*, 2022, **27**, 4249.
- 56 C. F. Chin, Q. Tian, M. I. Setyawati, W. Fang, E. S. Q. Tan, D. T. Leong and W. H. Ang, *J. Med. Chem.*, 2012, **55**, 7571–7582.
- 57 M. Ravera, E. Gabano, G. Pelosi, F. Fregonese, S. Tinello and D. Osella, *Inorg. Chem.*, 2014, **53**, 9326–9335.
- 58 V. Gandin, C. Marzano, G. Pelosi, M. Ravera, E. Gabano and D. Osella, *ChemMedChem*, 2014, **9**, 1299–1305.
- 59 P. S. Pregosin, *Coord. Chem. Rev.*, 1982, **44**, 247–291.
- 60 T. G. Appleton, J. R. Hall and S. F. Ralph, *Inorg. Chem.*, 1985, **24**, 673–677.
- 61 E. Gabano, E. Marengo, M. Bobba, E. Robotti, C. Cassino, M. Botta and D. Osella, *Coord. Chem. Rev.*, 2006, **250**, 2158–2174.
- 62 L. Ronconi and P. J. Sadler, *Coord. Chem. Rev.*, 2008, **252**, 2239–2277.
- 63 S. J. Berners-Price, L. Ronconi and P. J. Sadler, *Prog. Nucl. Magn. Reson. Spectrosc.*, 2006, **49**, 65–98.
- 64 P. Gramatica, E. Papa, M. Luini, E. Monti, M. B. Gariboldi, M. Ravera, E. Gabano, L. Gaviglio and D. Osella, *J. Biol. Inorg. Chem.*, 2010, **15**, 1157–1169.
- 65 M. Ravera, E. Gabano, I. Zanellato, F. Fregonese, G. Pelosi, J. A. Platts and D. Osella, *Dalton Trans.*, 2016, **45**, 5300–5309.
- 66 G. Ermondi, G. Caron, M. Ravera, E. Gabano, S. Bianco, J. A. Platts and D. Osella, *Dalton Trans.*, 2013, **42**, 3482–3489.
- 67 A. C. Tsipis and I. N. Karapetsas, *Dalton Trans.*, 2014, **43**, 5409–5426.
- 68 M. Ravera, E. Gabano, I. Zanellato, I. Bonarrigo, M. Alessio, F. Arnesano, A. Galliani, G. Natile and D. Osella, *J. Inorg. Biochem.*, 2015, **150**, 1–8.
- 69 J. A. Platts, G. Ermondi, G. Caron, M. Ravera, E. Gabano, L. Gaviglio, G. Pelosi and D. Osella, *J. Biol. Inorg. Chem.*, 2011, **16**, 361–372.
- 70 S. Z. Zhang, K. S. Lovejoy, J. E. Shima, L. L. Lagpacan, Y. Shu, A. Lapuk, Y. Chen, T. Komori, J. W. Gray, X. Chen, S. J. Lippard and K. M. Giacomini, *Cancer Res.*, 2006, **66**, 8847–8857.
- 71 J. J. Liu, J. Lu and M. J. McKeage, *Curr. Cancer Drug Targets*, 2012, **12**, 962–986.
- 72 I. Buss, A. Hamacher, N. Sarin, M. U. Kassack and G. V. Kalayda, *Metallomics*, 2018, **10**, 414–425.
- 73 E. Gabano, I. Zanellato, G. Pinton, L. Moro, M. Ravera and D. Osella, *Bioinorg. Chem. Appl.*, 2022, **2022**, 15.
- 74 M. Ravera, E. Gabano, I. Zanellato, B. Rangone, E. Perin, B. Ferrari, M. G. Bottone and D. Osella, *Dalton Trans.*, 2021, **50**, 3161–3177.
- 75 C. W. Strey, L. Schamell, E. Oppermann, A. Haferkamp, W. O. Bechstein and R. A. Blaheta, *Exp. Ther. Med.*, 2011, **2**, 301–307.
- 76 Y. Laxmi, K. J. Pierre, A. Elegbede, R. C. Wang and S. W. Carper, *Cancer Lett.*, 2007, **257**, 216–226.
- 77 M. Sanaei and F. Kavosi, *Asian Pac. J. Cancer Prev.*, 2021, **22**, 89–95.
- 78 X. Cao, J. Y. Hou, Q. L. An, Y. G. Assaraf and X. D. Wang, *Drug Resist. Updates*, 2020, **49**, 100671.
- 79 G. Y. Zhu, C. Y. Pan, J. X. Bei, B. Li, C. Liang, Y. Xu and X. M. Fu, *Front. Oncol.*, 2020, **10**, 595187.
- 80 E. Petruzzella, R. Sirota, I. Solazzo, V. Gandin and D. Gibson, *Chem. Sci.*, 2018, **9**, 4299–4307.
- 81 X. J. Ding, R. Zhang, R. P. Liu, X. Q. Song, X. Qiao, C. Z. Xie, X. H. Zhao and J. Y. Xu, *Inorg. Chem. Front.*, 2020, **7**, 1220–1228.
- 82 M. Gottlicher, S. Minucci, P. Zhu, O. H. Kramer, A. Schimpf, S. Giavara, J. P. Sleeman, F. Lo Coco, C. Nervi, P. G. Pelicci and T. Heinzel, *EMBO J.*, 2001, **20**, 6969–6978.
- 83 N. Gurvich, O. M. Tsygankova, J. L. Meinkoth and P. S. Kein, *Cancer Res.*, 2004, **64**, 1079–1086.
- 84 M. S. Kim, M. Blake, J. H. Baek, G. Kohlhausen, Y. Pommier and F. Carrier, *Cancer Res.*, 2003, **63**, 7291–7300.
- 85 J. Aparna and M. P. Brundha, *Indian J. Forensic Med. Toxicol.*, 2020, **14**, 4912–4926.
- 86 J. A. Eble and S. Niland, *Clin. Exp. Metastasis*, 2019, **36**, 171–198.
- 87 R. Dirziuvienė, L. Slekiene, J. Palubinskiene, I. Balnyte, K. Lasienė, D. Stakisaitis and A. Valanciute, *Histol. Histopathol.*, 2022, **37**, 1201–1212.
- 88 H. Zhu, B. Evans, P. O'Neill, X. C. Ren, Z. D. Xu, W. N. Hait and J. M. Yang, *Cancer Biol. Ther.*, 2009, **8**, 1722–1728.
- 89 B. C. Lewis, D. S. Klimstra, N. D. Socci, S. Xu, J. A. Koutcher and H. E. Varmus, *Mol. Cell. Biol.*, 2005, **25**, 1228–1237.



- 90 F. D. Rochon and L. M. Gruia, *Inorg. Chim. Acta*, 2000, **306**, 193–204.
- 91 R. K. Pathak, S. Marrache, J. H. Choi, T. B. Berding and S. Dhar, *Angew. Chem., Int. Ed.*, 2014, **53**, 1963–1967.
- 92 T. C. Johnstone, K. Suntharalingam and S. J. Lippard, *Chem. Rev.*, 2016, **116**, 3436–3486.
- 93 X. J. Li, Y. H. Liu and H. Q. Tian, *Bioinorg. Chem. Appl.*, 2018, **2018**, 8276139.

